Loading [MathJax]/jax/output/SVG/jax.js
Review Special Issues

Nanoparticle-based delivery platforms for mRNA vaccine development

  • Conventional vaccines have saved millions of lives, and new vaccines have also been developed; however, an urgent need for an efficient vaccine against SARS-CoV-2 showed us that vaccine development technologies should be improved more to obtain prophylactic agents rapidly during pandemic diseases. One of the next-generation vaccine technologies is utilization of mRNA molecules encoding antigens. The mRNA vaccines offer many advantages compared to conventional and other subunit vaccines. For instance, mRNA vaccines are relatively safe since they do not cause disease and mRNA does not integrate into the genome. mRNA vaccines also provide diverse types of immune responses resulting in the activation of CD4+ and CD8+ T cells. However, utilization of mRNA molecules also has some drawbacks such as degradation by ubiquitous nucleases in vivo. Nanoparticles (NPs) are delivery platforms that carry the desired molecule, a drug or a vaccine agent, to the target cell such as antigen presenting cells in the case of vaccine development. NP platforms also protect mRNA molecules from the degradation by nucleases. Therefore, efficient mRNA vaccines can be obtained via utilization of NPs in the formulation. Although lipid-based NPs are widely preferred in vaccine development due to the nature of cell membrane, there are various types of other NPs used in vaccine formulations, such as virus-like particles (VLPs), polymers, polypeptides, dendrimers or gold NPs. Improvements in the NP delivery technologies will contribute to the development of mRNA vaccines with higher efficiency.

    Citation: Sezer Okay, Öznur Özge Özcan, Mesut Karahan. Nanoparticle-based delivery platforms for mRNA vaccine development[J]. AIMS Biophysics, 2020, 7(4): 323-338. doi: 10.3934/biophy.2020023

    Related Papers:

    [1] Xiaowen Jia, Jingxia Chen, Kexin Liu, Qian Wang, Jialing He . Multimodal depression detection based on an attention graph convolution and transformer. Mathematical Biosciences and Engineering, 2025, 22(3): 652-676. doi: 10.3934/mbe.2025024
    [2] Shengfu Lu, Xin Shi, Mi Li, Jinan Jiao, Lei Feng, Gang Wang . Semi-supervised random forest regression model based on co-training and grouping with information entropy for evaluation of depression symptoms severity. Mathematical Biosciences and Engineering, 2021, 18(4): 4586-4602. doi: 10.3934/mbe.2021233
    [3] R. Loula, L. H. A. Monteiro . On the criteria for diagnosing depression in bereaved individuals: a self-organizing map approach. Mathematical Biosciences and Engineering, 2022, 19(6): 5380-5392. doi: 10.3934/mbe.2022252
    [4] Yanling An, Shaohai Hu, Shuaiqi Liu, Bing Li . BiTCAN: An emotion recognition network based on saliency in brain cognition. Mathematical Biosciences and Engineering, 2023, 20(12): 21537-21562. doi: 10.3934/mbe.2023953
    [5] Jiacan Xu, Donglin Li, Peng Zhou, Chunsheng Li, Zinan Wang, Shenghao Tong . A multi-band centroid contrastive reconstruction fusion network for motor imagery electroencephalogram signal decoding. Mathematical Biosciences and Engineering, 2023, 20(12): 20624-20647. doi: 10.3934/mbe.2023912
    [6] Xian Hua, Jing Li, Ting Wang, Junhong Wang, Shaojun Pi, Hangcheng Li, Xugang Xi . Evaluation of movement functional rehabilitation after stroke: A study via graph theory and corticomuscular coupling as potential biomarker. Mathematical Biosciences and Engineering, 2023, 20(6): 10530-10551. doi: 10.3934/mbe.2023465
    [7] R. Loula, L. H. A. Monteiro . Monoamine neurotransmitters and mood swings: a dynamical systems approach. Mathematical Biosciences and Engineering, 2022, 19(4): 4075-4083. doi: 10.3934/mbe.2022187
    [8] Enas Abdulhay, Maha Alafeef, Hikmat Hadoush, V. Venkataraman, N. Arunkumar . EMD-based analysis of complexity with dissociated EEG amplitude and frequency information: a data-driven robust tool -for Autism diagnosis- compared to multi-scale entropy approach. Mathematical Biosciences and Engineering, 2022, 19(5): 5031-5054. doi: 10.3934/mbe.2022235
    [9] Su-na Zhao, Yingxue Cui, Yan He, Zhendong He, Zhihua Diao, Fang Peng, Chao Cheng . Teleoperation control of a wheeled mobile robot based on Brain-machine Interface. Mathematical Biosciences and Engineering, 2023, 20(2): 3638-3660. doi: 10.3934/mbe.2023170
    [10] Yujie Kang, Wenjie Li, Jidong Lv, Ling Zou, Haifeng Shi, Wenjia Liu . Exploring brain dysfunction in IBD: A study of EEG-fMRI source imaging based on empirical mode diagram decomposition. Mathematical Biosciences and Engineering, 2025, 22(4): 962-987. doi: 10.3934/mbe.2025035
  • Conventional vaccines have saved millions of lives, and new vaccines have also been developed; however, an urgent need for an efficient vaccine against SARS-CoV-2 showed us that vaccine development technologies should be improved more to obtain prophylactic agents rapidly during pandemic diseases. One of the next-generation vaccine technologies is utilization of mRNA molecules encoding antigens. The mRNA vaccines offer many advantages compared to conventional and other subunit vaccines. For instance, mRNA vaccines are relatively safe since they do not cause disease and mRNA does not integrate into the genome. mRNA vaccines also provide diverse types of immune responses resulting in the activation of CD4+ and CD8+ T cells. However, utilization of mRNA molecules also has some drawbacks such as degradation by ubiquitous nucleases in vivo. Nanoparticles (NPs) are delivery platforms that carry the desired molecule, a drug or a vaccine agent, to the target cell such as antigen presenting cells in the case of vaccine development. NP platforms also protect mRNA molecules from the degradation by nucleases. Therefore, efficient mRNA vaccines can be obtained via utilization of NPs in the formulation. Although lipid-based NPs are widely preferred in vaccine development due to the nature of cell membrane, there are various types of other NPs used in vaccine formulations, such as virus-like particles (VLPs), polymers, polypeptides, dendrimers or gold NPs. Improvements in the NP delivery technologies will contribute to the development of mRNA vaccines with higher efficiency.


    Depression is a serious mental health problem that can be very harmful to individuals and society. Depression can seriously affect the emotional and psychological state of patients, causing them to feel sad, hopeless, and disinterested for long periods of time. This persistent low mood can cause a person to lose enthusiasm and motivation for life, affecting work, school and relationships. The World Health Organization (WHO) [1] highlights that depression is one of the most common mental illnesses in the world, with approximately 340 million people worldwide suffering from depression. This means that about one in 20 people are affected by depression. Early and accurate diagnosis and timely and effective treatment are essential to minimizing the harm caused by depression.

    The treatment of depression continues to pose challenges despite years of development. Antidepressant drugs exert their therapeutic effects by modulating the interaction of neurotransmitter systems across multiple brain regions. Different types of antidepressants use different principles and mechanisms to treat depression. Healthy subjects receiving venlafaxine showed a decrease in theta-band rhythms in the midline-and-right-frontal (MRF) region at 48 hours and at 1 week after randomization [2]. Selective serotonin reuptake inhibitors may restore abnormal brain activity in the inferior frontal cortex of patients [3]. However, successive empirical attempts to identify initial resistance to antidepressant treatment can complicate clinical drug therapy progressively [4]. Thus, the exact medication regimen to be used needs to be carefully considered.

    Like medication, transcranial magnetic stimulation (TMS) is a commonly used clinical treatment for depression. TMS is a non-invasive technique that utilizes a magnetic field to induce electrical currents that stimulate specific areas of the brain under an applied coil. Noda et al. used TMS to repetitively stimulate the right prefrontal cortex of depressed patients. This resulted in rapid modulation of EEG activity in depressed patients [5]. Hutton et al. found that stimulation of the left dorsolateral prefrontal lobe of the brain using high-frequency TMS was effective in alleviating depressive symptoms [6]. They concluded that different TMS stimulation programs have different therapeutic effects on depressed patients. Therefore, studying the functional abnormalities of brain regions in patients with depression is crucial for the development and improvement of clinical treatment programs. Neuroimaging techniques are widely used in depression research. Electroencephalography and functional magnetic resonance imaging (fMRI) techniques have been shown to be effective and reliable in studying functional brain abnormalities in patients.

    Functional connectivity is the statistical correlation between different regions within the brain, which reflects the functional collaboration and communication between brain regions. Changes in functional connectivity may indicate the neurobiological basis of disease and can serve as a biomarker for diagnosis and assessment of therapeutic efficacy. Naho et al. [7] found that antidepressants had a heterogeneous effect on the identified FCs of 25 melancholic MDDs. They suggested that regions with abnormal functional connectivity such as the left dorsolateral prefrontal cortex, inferior frontal gyrus, and others could be targets for future optimization of depression treatment regimens. Hui et al. [8] found that mindfulness-based cognitive therapy strengthened functional connections between the amygdala and middle frontal gyrus, and this increase in communication correlated with improvements in clinical symptoms.

    Effective connectivity is one of the common EEG indicators of functional networks. It describes the causal relationships between different brain regions and the way information is transmitted and interacts in the brain [9]. By inferring the directionality and strength of information transfer, researchers can construct a more accurate brain connectivity map that reveals the functional connectivity patterns between different brain regions. For instance, Alena et al. utilized partial directed coherence (PDC) to evaluate the overall efficiency of the entire brain and graph-theoretic metrics of specific structures, identifying the significant role of the amygdala in depression [10]. In another study, Olejarczyk et al. employed direct transfer function (DTF) to assess the therapeutic effects of transcranial magnetic stimulation and determine the most suitable stimulation protocol [11].

    However, the prediction models based on PDC and DTF have certain limitations and lack flexibility in capturing the frequency domain characteristics of nonlinear systems. These models are applicable to lengthy low-latitude data series. Otherwise, the problem of data interference and dimension explosion will occur. Thus, it is difficult to handle multivariate systems like EEG signals.

    PTE is an information-theoretic method that provides insights into the direction of information transfer, indicating which variable exerts a greater influence on another variable [12]. This is crucial for understanding causality and information flow within complex systems. Unlike other methods, PTE can detect nonlinear causality and information transfer without relying on a specific model of the input data. It is particularly well-suited for estimating directional connectivity in brain networks based on phase information. In the context of resting-state functional networks, the directional changes in preferred information flow between sources can be effectively studied using directional phase transfer entropy (dPTE) [13]. As a result, PTE offers significant advantages in analyzing information flow within brain networks and resting-state functional networks. It not only indicates the strength of connectivity between brain regions in the same way as conventional functional connectivity metrics, but also indicates the directionality of that connectivity in the same way as the PDC predictive model.

    We used standard low-resolution electromagnetic tomography (sLORETA) [14] to calculate current density distributions in various regions of the brain. In this way, an adaptive spatial model of the scalp source was constructed. EEG signals based on lead orientation can be converted to anatomically based time series so that the time series correspond to the scalp spatial model signal sources. Compared to the lead position method, the signal source localization method is more suitable for brain partitioning. This makes the processed data more interpretable.

    We also calculated the partial transfer entropy (PTE) index between each pair of time series and considered not only the strength of functional connectivity, but also the ability to determine the specific direction of information flow. dPTE requires no input model data and is well suited to estimating the connectivity of large-scale human brain networks. Statistical analyses of dPTE feature matrices of different dimensions were performed for depressed and healthy individuals. We analyzed depression EEG in different frequency bands, lobes, brain regions with abnormal connectivity and characteristics of information flow between brain regions. These findings can provide excellent support and a reliable basis for the implementation of clinical treatment protocols for depression.

    The organization of the paper is as follows: In the second section, we describe our research methodology and experimental design as well as demographic data statistics of the subjects. In the third section, we present the results of the experiment, including the statistical analysis of the data and the analysis of the indicators. In the fourth section, we provide an in-depth discussion of these results, explore their additions to the literature and their implications at the theoretical and applied levels, summarize our major findings, and propose directions for future research.

    We recruited 22 depressed adolescents and 22 healthy adolescents, and the difference in age between the two groups was not statistically significant (p > 0.05). The subjects were right-handed, with normal or corrected vision, no history of mental illness, drug addiction, or alcoholism, and were all tested and diagnosed by a professional doctor using the Hamilton Depression Scale in a hospital in Changzhou City. Normal subjects had HAMD scores around 3, while depressed subjects had scores as high as around 20.

    Before the experiment, all were informed of the details of the experiment and signed an informed consent form with the subjects and their guardians to participate in this experiment voluntarily. EEG signals were collected from subjects in the resting state with eyes open for 5 minutes and eyes closed for 5 minutes. The experimental environment was quiet, had a comfortable temperature, there was no noise and visual interference, and the subjects were asked to sit still and stay awake, avoiding large movements as much as possible.

    Table 1.  Demographic and clinical data for patients with depression and controls groups.
    Variables Healthy group Depressed patients P-value
    Sex ratio, male/female 11/11 12/10 NA
    Age (years) 16.25±1.4 16.17±0.96 0.91
    Education(years) 9.2±1.52 9±1.71 0.54
    Observer-rated depression scale (HAMD-17) 3.2±1.64 20.3±4.7 < 0.001
    Handedness (left/right) 0/22 0/22 NA
    The Mann-Whitney U test was used for age, age at education, and HAME scale scores.

     | Show Table
    DownLoad: CSV

    EEG data acquisition was performed using a 64-lead EEG acquisition system from EGI with Net Station software, with the electrode position distribution based on the 10-10 international standard, the reference electrode being the Cz electrode, the sampling frequency being 500 Hz, and the upper limit of the electrode impedance being set to 50 kΩ.

    The raw data collected were processed to make it compatible with MATLAB software by converting it into a raw format using Net Station software. Subsequently, the data underwent preprocessing using the EEGLAB toolbox (version 2022), following these specific steps: band-pass filtering from 0.5 Hz to 45 Hz, reconversion of the reference point to an average reference, removal of artifacts such as blinks and head movements using independent component analysis (ICA), and replacement of bad leads with signal drift by averaging the data overlay with neighboring leads. Finally, a 3-minute clean data segment was selected for further analysis.

    We employed a rigorous approach to map cortical current source density (CSD) utilizing a distributed model comprising 15,000 current dipoles. The spatial distribution and orientations of these dipoles were determined based on cortical regions defined in the brain neurological institute (MNI) standard brain model [15]. To ensure compatibility with the sensor network's geometry, the MNI model was suitably adapted. The cortical model for EEG analysis was generated using the openMEEG boundary element method [16], which calculated a source space model of the cortical surface in a block-by-block fashion. In order to mitigate the impact of slow bias in the data, the noise covariance was diligently computed.

    The standard MNLS solution is given by the following equation:

    j=argminmLj+λj∥=TmwithT=LT[LLT+λ1] (1)

    where j is the unknown current density vector, m is the measured data vector, L is the leading field matrix, † denotes the Moore-Penrose pseudo-inverse matrix, and 1 is the unit matrix.

    In the Bayesian view, the potential variance Sm is a function of the noise variance Sm,noise=λ1 and the prior source variance Sj,prior=1:

    Sm=LSj,priorLT+Sm,noise=LLT+λ1 (2)

    The variance Sj of the estimated current density j is given by the following equation:

    Sj=TSmTT=LT[LSj,priorLT+λ1] (3)

    The sLORETA metric of the source location k is computed as based on its corresponding 3-dimensional subvector jk and the 3 × 3 block diagonal elements Sj,k of the covariance matrix Sj :

    jkT[Sj,k]1jk (4)

    sLORETA can be written as a linear operator applied to the data vector m:

    [Sj,k]0.5jk=[Sj,k]0.5Tkm (5)

    where Tk denotes the row in T associated with k. The activation of 15,000 dipoles was computed from the EEG time series using a weighted minimum-paradigm estimator.

    Finally, according to the Desikan-Killiany (DK) Brain Atlas [17], dipoles were categorized into 68 regions of interest (ROIs). The activity of each ROI was generated by averaging the CSDs of all voxels within that region. The 68 ROIs were further categorized into 14 regions based on their anatomical location on the cortex: LPF, RPF, LF, RF, LC, RC, LP, RP, LO, RO, LT, RT, LL, and RL.

    PTE is a transfer entropy of signal phase time series based on the transfer entropy (TE) principle, which is suitable to study information transfer in high-lead EEG signals.

    TE is a metric that measures the transfer of information between stochastic processes. It is based on the comparison of conditional and joint probabilities and is used to describe the degree of causal influence of one random variable on another. Transfer entropy measures the flow of information from one random variable X to another random variable Y. The formula for transfer entropy is:

    TE(XY)=H(Y|Y')H(Y|Y',X') (6)

    where H(Y|Y') is the conditional entropy of the Y value at the current moment given the Y value Y' at the past moment; H(Y|Y', X') is the conditional entropy of the Y value at the current moment given the Y value Y' and X value X' at the past moment. A positive transfer entropy indicates that X has a causal effect on Y, and a zero or negative entropy indicates that X has no causal effect on Y.

    PTE estimates the strength of the causal relationship between two signals based on the instantaneous phase difference computed using the Hilbert transform and controls for possible causal effects of other signals. It is often used to assess causal relationships between a wider range of variables:

    PTE(XY)=I(θy(t),θx(t')|θy(t')) (7)

    where θx(t′) and θy(t′) are the past states of the instantaneous phase time series of X(t) and Y(t) at t′ = t - δt, respectively. There is no specific upper limit on the PTE; thus, we normalize the PTE using the dPTE:

    dPTExy=PTExy/(PTExy+PTEyx) (8)

    The value of dPTExy ranges from 0 to 1. For dPTExy > 0.5, the signal flows preferentially from X to Y, and for dPTExy < 0.5, the signal flows from Y to X. Subtracting 0.5 for all dPTExy, the information flow direction is defined in terms of positive and negative.

    We apply dPTE to high-lead EEG and using dPTE in the 0.5-48 Hz frequency range to estimate the directional FC between all combinations of the corresponding source time series and extracting significant network connections using alignment tests. In order to ascertain the clear directionality of information flow between two regions of interest (ROIs), a nonparametric alignment test was employed. To validate the strength of the information flow, 5,000 random permutations were conducted for each dPTE value. This procedure determined whether the observed information flow was significantly different from zero. The null distribution was symmetrically generated around the mean of the null hypothesis. Subsequently, p-values were obtained for each state of consciousness, and these p-values were adjusted for multiple comparisons using the tmax method to effectively control for family-wise error rates.

    In this study, a second-order Butterworth bandpass filter was used to divide the signal into four frequency bands: delta (0.5-4 Hz), theta (4-8 Hz), alpha (8-13 Hz), and beta (13-30 Hz). For each band, we split the backtracked time series into smaller windows (5 seconds long) to generate the dPTE matrix and average it.

    To assess the differences between groups, Friedman's test was employed to determine the number of information flows exhibiting significant disparities across various brain regions. Regions of interest (ROIs) displaying significant differences between groups were further analyzed, and their corresponding directed Partial Transfer Entropy (dPTE) values were extracted as feature datasets for classification validation. To investigate the discriminative capacity of the depression detection indices under investigation, a SVM classifier was selected for 5-fold cross-validation. The performance of the classifier was evaluated based on criteria such as specificity, sensitivity, and accuracy.

    Figure 1.  Flow chart of depression brain information flow analysis technique.

    The PTE data were subjected to normalization, resulting in a dPTE matrix with values ranging from 0 to 1. Since the distribution of dPTE values did not conform to a normal distribution, we use the nonparametric permutation test to confirm that the information flow between two ROIs has a clear directionality. The permutation test involved creating a dataset comprising information flow intensities from all subjects, followed by 5,000 random permutations to assess whether the information flow intensities significantly deviated from zero. The null distribution was symmetrically centered around the mean of the null hypothesis. A p-value was obtained for each state of consciousness, and multiple corrections using the "tmax" method were applied to control for family-wise error rates.

    Figure 2.  Significant directional connectivity matrices in four frequency bands for depressed patients and controls. The color blocks in the xth row and yth column of each connection matrix indicate the dPTE values of the xth ROI flowing to the yth ROI: dPTExy.

    The dPTExy value is between 0 and 1. When 0.5 < dPTExy < 1, it means that the information flow is prioritized from x to y; When 0 < dPTExy < 0.5, it means that the information flow is from y to x; When dPTExy, = 0 it indicates that the information flow between signal x and signal y is in equilibrium.

    Among them, delta and theta frequency bands had less significant information flow, and alpha and beta significant information flow was more. Moreover, in all frequency bands, the intensity of information flow was higher in the healthy group of subjects than in the depressed group.

    The 68 time series were reordered according to brain partitioning and a Friedman test was performed between groups. As shown in Figure 3, the between-group differences between the depressed and subject groups were concentrated in the theta and alpha bands, and the regions presenting differences were relatively concentrated. For this reason, the amount of information flow from each region to the other regions was counted. Brain regions were divided into LPF, RPF, LF, RF, LC, RC, LP, RP, LO, RO, LT, RT, LL, and RL according to the DK partitioning. The number of information streams generated by ROIs within each region was averaged after summation, and the results are shown in Figure 4.

    Figure 3.  Results of Friedman's test between groups.
    Figure 4.  Number of information flows in brain regions.

    Significant differences in brain connectivity were observed between the depressed and healthy groups. Specifically, these differences were found to be more prominent in the right hemisphere regions compared to the left hemisphere regions. The occipital regions exhibited greater disparities in connectivity compared to other brain regions. Notably, the differences in connectivity within the right central hook region were particularly pronounced in the alpha frequency band.

    There was a significant increase in information flow between the two halves of the brain in depressed subjects, but there is a lack of information flow between more distant brain regions. The brain regions corresponding to the DK template are shown in Table 2. Using the values of information flow with significant differences between alpha and theta in Figure 5 as a dataset, the model performance achieves 91% correctness using an SVM classifier with a five-fold cross-validation.

    Table 2.  Brain regions showing significant differences in information flow.
    Delta Theta Alpha Beta
    LO 0.037*
    cuneus
    RPF 0.009**
    frontal pole
    RT 0.025*
    entorhinal
    LT 0.046*
    superior temporal
    RP 0.041*
    supramarginal
    LP 0.029*
    supramarginal
    RF 0.005**
    Pars triangularis
    RL 0.036*
    rostral anterior cingulate
    RC 0.007**
    paracentral
    RT 0.004**
    parahippocampal
    RO 0.004**
    Lateral occipital
    LF 0.028*
    superior frontal
    RT 0.045*
    middle temporal
    RPF 0.014*
    pars orbitalis
    LO 0.038**
    lateral occipital
    LF 0.14*
    caudal middle frontal
    RT 0.17*
    entorhinal
    T 0.43*
    middle temporal
    LT 0.004**
    parahippocampal
    RO 0.007**
    pericalcarine
    RC 0.002**
    precentral
    RP 0.006**
    inferior parietal
    RT 0.029*
    temporal pole

     | Show Table
    DownLoad: CSV
    Figure 5.  Information flow loops. The solid lines indicate significant directed information flow between the two ROIs (permutation test, P < 0.05), blue lines indicate stronger information flow in the healthy group than in the depressed group, and green lines indicate stronger information flow in the depressed group than in the healthy group.

    To mitigate the negative effects of depression on patients and to aid in the development of a drug or TMS programs, it would be useful to study abnormalities in the areas of brain function associated with depression and abnormalities in the connections between brain regions. Researchers using functional magnetic resonance imaging have successfully identified different areas of the brain with impaired function in patients with different subtypes of depression [18]. Although fMRI provides valuable information, the equipment is expensive and not easy to use. In contrast, EEG technology is inexpensive, easy to administer, and is an important tool for clinical assessment and community screening.

    Most EEG studies rely to some extent on graph theory to categorize and identify subjects through functional connectivity matrices. Hasanzadeh et al. [12] reported that depressed individuals have stronger than normal brain functional connectivity and a more randomized brain network structure. Although these biomarkers achieved high classification accuracy, graph theoretic results are difficult to interpret physiologically. However, Orgo et al. [19] found that the inclusion of graph theory metrics did not significantly improve the accuracy of functional connectivity metrics in distinguishing between depressed and control groups. Therefore, it remains a challenge to study the effects between depressive foci and brain regions to complement clinical medication and therapeutic modalities such as transcranial magnetic stimulation.

    In this study, we investigated whether the functional connectivity between certain brain regions in the EEG signals of depressed patients is abnormal in the resting state and whether there are differences in the direction of information flow compared to the healthy group. We tracked EEG signals using sLORETA and then calculated the PTE effective connectivity matrix. By performing a permutation test on the data from all subjects, we found that the overall information flow in resting-state EEG occurs predominantly in the alpha and beta frequency bands. Notably, the healthy group showed a higher intensity of overall information flow compared to the depressed group. This observation may be due to the inverse relationship between alpha power and cortical activity. That is, a decrease in alpha power in the posterior regions of the brain may indicate an increase in neuronal excitability.

    We performed Friedman's test on the PTE matrix to compare the healthy and depressed groups and found significant differences in the alpha and beta frequency bands. Specifically, the depressed group showed increased interhemispheric connectivity and decreased teleconnection. This increased interhemispheric functional connectivity may be due to the disruption of corpus callosum integrity [20], resulting in imbalances in hemispheric functional coordination. In addition, depressed patients showed reduced grey matter volume in the left precentral gyrus and increased grey matter volume in the right thalamus [21]. These abnormal grey matter volumes and connectivity patterns reflect abnormal intrinsic wiring costs of brain structures, resulting in atypical topological properties of functional connectivity.

    Comparing the two groups of subjects, we observed greater differences in the right than in the left brain regions, especially in the right central lobe region, where the differences in the alpha band were most pronounced. theta and beta bands in the left occipital and right frontal lobes showed similar characteristics. In addition, the intensity of information flow was consistent with depression scores. Similarly, Carola et al. found increased functional connectivity in the right frontal and central regions of the brain in depressed patients [22]. A study of transcranial magnetic stimulation targeting isolated cerebral hemispheres showed the potential to alleviate cerebral hemispheric imbalances and was effective in improving core depressive factors and anxiety symptoms in patients [23].

    Other researchers looked at lesions in the occipital and right frontal lobes and found that occipital curvature was more common in depressed people than in healthy people. Occipital asymmetry and occipital curvature, although different phenomena, may be due to incomplete neural pruning, limited cranial space for brain growth, or ventricular enlargement exacerbating the natural occipital curvature pattern, resulting in brain compression and the need to 'wrap' the other occipital lobe [24]. A recent meta-analysis showed that hyperconnectivity in the prefrontal and anterior cingulate regions of the default mode network (DMN) is primarily associated with rumination, highlighting the critical role of prefrontal regions in this process [25]. In contrast, hemodynamic activation in the right dorsolateral prefrontal cortex (DLPFC) and right frontal pole cortex (FPC) was significantly increased in the anxious-depressed group compared to the non-anxious-depressed and healthy groups [26].

    There was also a significant increase in the strength of information flow from the parahippocampal gyrus and middle temporal gyrus in the temporal lobe. Researchers using functional magnetic resonance imaging found a higher prevalence of hippocampal structural abnormalities in depressed patients, accompanied by increased activity within the brain's default mode network and increased extratemporal activation compared to the non-depressed group [27]. In particular, abnormal and excessive functional connectivity was observed in the right parietal lobe across both the delta and beta frequency bands, particularly in relation to the left central hook. Hou et al. targeted the parietal lobe and observed significant rehabilitative outcomes following four weeks of neurofeedback training [28].

    In summary, extensive research has consistently shown significant inter-individual variability in the neurophysiological features associated with depressive symptoms. Rather than being limited to specific local changes, pathophysiological changes in depression appear to involve multiple brain regions [29]. We found that depression is associated with abnormalities in information flow within regions such as the occipital lobe, right frontal lobe, right temporal lobe and central sulcus. The depressed patients generally showed a decrease in long-range information flow between the ipsilateral anterior and posterior regions of the brain, and an increase in information flow between hemispheres. Notably, these connectivity differences were more pronounced in the right side of the brain compared to the left side. The data set used in this study consisted of dPTE values representing information flow and showed statistically significant differences in the alpha and theta bands, with a classification accuracy of 91%. These findings suggest that these abnormalities may contribute to depressive episodes. Given the variability between patients and the potential differences in underlying pathogenesis, future treatment protocols for depression should take these factors into account. Our approach may help clinicians to develop individualized treatment plans tailored to the specific needs of each depressed individual.

    The authors declared that they have no conflicts of interest to this work.

    The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.

    This work is partly supported by the project of Jiangsu Key Research and Development Plan (BE2021012-5 and BE2021012-2), Changzhou Science and Technology Bureau Plan (CE20225034), Key Laboratory of Brain Machine Collaborative Intelligence Foundation of Zhejiang Province (2020E10010-04), and Human-Machine Intelligence and Interaction International Joint Laboratory Project.

    Please contact the correspondence authors for data request.



    Conflict of interest



    The authors declare no conflict of interest.

    [1] Sharp PA (2009) The centrality of RNA. Cell 136: 577-580.
    [2] Cooper TA, Wan L, Dreyfuss G (2009) RNA and disease. Cell 136: 777-793.
    [3] Fry LE, Patrício MI, Williams J, et al. (2019) Association of messenger RNA level with phenotype in patients with choroideremia: potential implications for gene therapy dose. JAMA Ophthalmol 138: 128-135.
    [4] Li B, Zhang X, Dong Y (2019) Nanoscale platforms for messenger RNA delivery. Wires Nanomed Nanobi 11: e1530.
    [5] Midoux P, Pichon C (2015) Lipid-based mRNA vaccine delivery systems. Expert Rev Vaccines 14: 221-234.
    [6] Dannull J, Haley NR, Archer G, et al. (2013) Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest 123: 3135-3145.
    [7] Van Lint S, Heirman C, Thielemans K, et al. (2013) mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vacc Immunother 9: 265-274.
    [8] Yang J, Arya S, Lung P, et al. (2019) Hybrid nanovaccine for the co-delivery of the mRNA antigen and adjuvant. Nanoscale 11: 21782-21789.
    [9] Le TT, Andreadakis Z, Kumar A, et al. (2020) The COVID-19 vaccine development landscape. Nat Rev Drug Discov 19: 305-306.
    [10] Geall AJ, Mandl CW, Ulmer JB (2013) RNA: the new revolution in nucleic acid vaccines. Semin Immunol 25: 152-159.
    [11] Pardi N, Hogan MJ, Porter FW, et al. (2018) mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov 17: 261-279.
    [12] Pascolo S (2015) The messenger's great message for vaccination. Expert Rev Vaccines 14: 153-156.
    [13] Deering RP, Kommareddy S, Ulmer JB, et al. (2014) Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin Drug Deliv 11: 885-899.
    [14] Liu MA (2010) Immunologic basis of vaccine vectors. Immunity 33: 504-515.
    [15] Jäschke A, Helm M (2003) RNA sex. Chem Biol 10: 1148-1150.
    [16] Pollard C, Rejman J, De Haes W, et al. (2013) Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther 21: 251-259.
    [17] Vallazza B, Petri S, Poleganov MA, et al. (2015) Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond. Wiley Interdiscip Rev RNA 6: 471-499.
    [18] Gómez-Aguado I, Rodríguez-Castejón J, Vicente-Pascual M, et al. (2020) Nanomedicines to deliver mRNA: State of the art and future perspectives. Nanomaterials 10: 364.
    [19] Versteeg L, Almutairi MM, Hotez PJ, et al. (2019) Enlisting the mRNA vaccine platform to combat parasitic infections. Vaccines 7: 122.
    [20] Hekele A, Bertholet S, Archer J, et al. (2013) Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect 2: e52.
    [21] Lindgren G, Ols S, Liang F, et al. (2017) Induction of robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells. Front Immunol 8: 1539.
    [22] Luo F, Zheng L, Hu Y, et al. (2017) Induction of protective immunity against Toxoplasma gondii in mice by nucleoside triphosphate hydrolase-II (NTPase-II) self-amplifying RNA vaccine encapsulated in lipid nanoparticle (LNP). Front Microbiol 8: 605.
    [23] Michel T, Golombek S, Steinle H, et al. (2019) Efficient reduction of synthetic mRNA induced immune activation by simultaneous delivery of B18R encoding mRNA. J Biol Eng 13: 40.
    [24] Appay V, Douek DC, Price DA (2008) CD8+ T cell efficacy in vaccination and disease. Nat Med 14: 623-628.
    [25] Pardi N, Hogan MJ, Naradikian MS, et al. (2018) Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med 215: 1571-1588.
    [26] Zarghampoor F, Azarpira N, Khatami SR, et al. (2019) Improved translation efficiency of therapeutic mRNA. Gene 707: 231-238.
    [27] Kowalski PS, Rudra A, Miao L, et al. (2019) Delivering the messenger: Advances in technologies for therapeutic mRNA delivery. Mol Ther 27: 710-728.
    [28] Reichmuth AM, Oberli MA, Jaklenec A, et al. (2016) mRNA vaccine delivery using lipid nanoparticles. Ther Deliv 7: 319-334.
    [29] Lundstrom K (2009) Alphaviruses in gene therapy. Viruses 1: 13-25.
    [30] Chira S, Jackson CS, Oprea I, et al. (2015) Progresses towards safe and efficient gene therapy vectors. Oncotarget 6: 30675-30703.
    [31] Ku SH, Jo SD, Lee YK, et al. (2016) Chemical and structural modifications of RNAi therapeutics. Adv Drug Deliv Rev 104: 16-28.
    [32] Presnyak V, Alhusaini N, Chen YH, et al. (2015) Codon optimality is a major determinant of mRNA stability. Cell 160: 1111-1124.
    [33] Thess A, Grund S, Mui BL, et al. (2015) Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther 23: 1456-1464.
    [34] Wojtczak BA, Sikorski PJ, Fac-Dabrowska K, et al. (2018) 5′-phosphorothiolate dinucleotide cap analogues: Reagents for messenger RNA modification and potent small-molecular inhibitors of decapping enzymes. J Am Chem Soc 140: 5987-5999.
    [35] Li B, Luo X, Dong Y (2016) Effects of chemically modified messenger RNA on protein expression. Bioconjug Chem 27: 849-853.
    [36] Li M, Zhao M, Fu Y, et al. (2016) Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways. J Control Release 228: 9-19.
    [37] Svitkin YV, Cheng YM, Chakraborty T, et al. (2017) N1-methyl-pseudouridine in mRNA enhances translation through eIF2a-dependent and independent mechanisms by increasing ribosome density. Nucleic Acids Res 45: 6023-6036.
    [38] Oberg AL, Kennedy RB, Li P, et al. (2011) Systems biology approaches to new vaccine development. Curr Opin Immunol 23: 436-443.
    [39] Auffan M, Rose J, Bottero JY, et al. (2009) Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective. Nat Nanotechnol 4: 634-641.
    [40] Treuel L, Jiang X, Nienhaus GU (2013) New views on cellular uptake and trafficking of manufactured nanoparticles. J R Soc Interface 10: 20120939.
    [41] Ulkoski D, Bak A, Wilson JT, et al. (2019) Recent advances in polymeric materials for the delivery of RNA therapeutics. Expert Opin Drug Deliv 16: 1149-1167.
    [42] Pérez-Ortín JE, Alepuz P, Chávez S, et al. (2013) Eukaryotic mRNA decay: Methodologies, pathways, and links to other stages of gene expression. J Mol Biol 425: 3750-3775.
    [43] Pati R, Shevtsov M, Sonawane A (2018) Nanoparticle vaccines against infectious diseases. Front Immunol 9: 2224.
    [44] Means TK, Hayashi F, Smith KD, et al. (2003) The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol 170: 5165-5175.
    [45] Boraschi D, Italiani P, Palomba R, et al. (2017) Nanoparticles and innate immunity: new perspectives on host defence. Semin Immunol 34: 33-51.
    [46] Chen YS, Hung YC, Lin WH, et al. (2010) Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide. Nanotechnology 21: 195101.
    [47] Wang T, Zou M, Jiang H, et al. (2011) Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant. Eur J Pharm Sci 44: 653-659.
    [48] Xu L, Liu Y, Chen Z, et al. (2012) Surface-engineered gold nanorods: promising DNA vaccine adjuvant for HIV-1 treatment. Nano Lett 12: 2003-2012.
    [49] Tao W, Gill HS (2015) M2e-immobilized gold nanoparticles as influenza A vaccine: role of soluble M2e and longevity of protection. Vaccine 33: 2307-2315.
    [50] Li X, Deng X, Huang Z (2001) In vitro protein release and degradation of poly-d-L-lactide-poly(ethylene glycol) microspheres with entrapped human serum albumin: quantitative evaluation of the factors involved in protein release phases. Pharm Res 18: 117-124.
    [51] Chahal JS, Fang T, Woodham AW, et al. (2017) An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. Sci Rep 7: 252.
    [52] Chahal JS, Khan OF, Cooper CL, et al. (2016) Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci U S A 113: E4133-E4142.
    [53] Sharifnia Z, Bandehpour M, Hamishehkar H, et al. (2019) In-vitro transcribed mRNA delivery using PLGA/PEI nanoparticles into human monocyte-derived dendritic cells. Iran J Pharm Res 18: 1659-1675.
    [54] Uchida S, Kinoh H, Ishii T, et al. (2016) Systemic delivery of messenger RNA for the treatment of pancreatic cancer using polyplex nanomicelles with a cholesterol moiety. Biomaterials 82: 221-228.
    [55] Kaczmarek JC, Patel AK, Kauffman KJ, et al. (2016) Polymer-lipid nanoparticles for systemic delivery of mRNA to the lungs. Angew Chem Int Ed Engl 55: 13808-13812.
    [56] Patel AK, Kaczmarek JC, Bose S, et al. (2019) Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium. Adv Mater 31: e1805116.
    [57] Liu Y, Li Y, Keskin D, et al. (2019) Poly(β-amino esters): Synthesis, formulations, and their biomedical applications. Adv Healthc Mater 8: e1801359.
    [58] Capasso Palmiero U, Kaczmarek JC, Fenton OS, et al. (2018) Poly(β-amino ester)-co-poly(caprolactone) terpolymers as nonviral vectors for mRNA delivery in vitro and in vivo. Adv Healthc Mater 7: e1800249.
    [59] Palamà IE, Cortese B, D'Amone S, et al. (2015) mRNA delivery using non-viral PCL nanoparticles. Biomater Sci 3: 144-151.
    [60] Lacroix C, Humanes A, Coiffier C, et al. (2020) Polylactide-based reactive micelles as a robust platform for mRNA delivery. Pharm Res 37: 30.
    [61] Dong Y, Dorkin JR, Wang W, et al. (2016) Poly(glycoamidoamine) brushes formulated nanomaterials for systemic siRNA and mRNA delivery in vivo. Nano Lett 16: 842-848.
    [62] Palmerston Mendes L, Pan J, Torchilin VP (2017) Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules 22: 1401.
    [63] Franiak-Pietryga I, Ziemba B, Messmer B, et al. (2018) Dendrimers as drug nanocarriers: the future of gene therapy and targeted therapies in cancer. Dendrimers: Fundamentals and Applications IntechOpen, 7.
    [64] Islam MA, Xu Y, Tao W, et al. (2018) Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat Biomed Eng 2: 850-864.
    [65] Hajam IA, Senevirathne A, Hewawaduge C, et al. (2020) Intranasally administered protein coated chitosan nanoparticles encapsulating influenza H9N2 HA2 and M2e mRNA molecules elicit protective immunity against avian influenza viruses in chickens. Vet Res 51: 37.
    [66] McCullough KC, Bassi I, Milona P, et al. (2014) Self-replicating replicon-RNA delivery to dendritic cells by chitosan-nanoparticles for translation in vitro and in vivo. Mol Ther Nucleic Acids 3: e173.
    [67] Maiyo F, Singh M (2019) Folate-targeted mRNA delivery using chitosan-functionalized selenium nanoparticles: potential in cancer immunotherapy. Pharmaceuticals (Basel) 12: 164.
    [68] Son S, Nam J, Zenkov I, et al. (2020) Sugar-nanocapsules imprinted with microbial molecular patterns for mRNA vaccination. Nano Lett 20: 1499-1509.
    [69] Siewert C, Haas H, Nawroth T, et al. (2019) Investigation of charge ratio variation in mRNA - DEAE-dextran polyplex delivery systems. Biomaterials 192: 612-620.
    [70] Zeng C, Zhang C, Walker PG, et al. (2020) Formulation and delivery technologies for mRNA vaccines. Current Topics in Microbiology and Immunology Berlin: Springer.
    [71] Scheel B, Teufel R, Probst J, et al. (2005) Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 35: 1557-1566.
    [72] Schlake T, Thess A, Fotin-Mleczek M, et al. (2012) Developing mRNA-vaccine technologies. RNA Biol 9: 1319-1330.
    [73] Fotin-Mleczek M, Duchardt KM, Lorenz C, et al. (2011) Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 34: 1-15.
    [74] Schnee M, Vogel AB, Voss D, et al. (2016) An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl Trop Dis 10: e0004746.
    [75] Udhayakumar VK, De Beuckelaer A, McCaffrey J, et al. (2017) Arginine-rich peptide-based mRNA nanocomplexes efficiently instigate cytotoxic T cell immunity dependent on the amphipathic organization of the peptide. Adv Healthc Mater 6: 1601412.
    [76] Coolen AL, Lacroix C, Mercier-Gouy P, et al. (2019) Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation. Biomaterials 195: 23-37.
    [77] Jekhmane S, De Haas R, Paulino da Silva Filho O, et al. (2017) Virus-like particles of mRNA with artificial minimal coat proteins: particle formation, stability, and transfection efficiency. Nucleic Acid Ther 27: 159-167.
    [78] Li J, Sun Y, Jia T, et al. (2014) Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer. Int J Cancer 134: 1683-1694.
    [79] Sun S, Li W, Sun Y, et al. (2011) A new RNA vaccine platform based on MS2 virus-like particles produced in saccharomyces cerevisiaeBiochem Biophys Res Commun 407: 124-128.
    [80] Zhitnyuk Y, Gee P, Lung MSY, et al. (2018) Efficient mRNA delivery system utilizing chimeric VSVG-L7Ae virus-like particles. Biochem Biophys Res Commun 505: 1097-1102.
    [81] Kauffman KJ, Webber MJ, Anderson DG (2016) Materials for non-viral intracellular delivery of messenger RNA therapeutics. J Control Release 240: 227-234.
    [82] Kulkarni JA, Cullis PR, Van Der Meel R (2018) Lipid nanoparticles enabling gene therapies: From concepts to clinical utility. Nucleic Acid Ther 28: 146-157.
    [83] Dimitriadis GJ (1978) Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes. Nature 274: 923-924.
    [84] Moon JJ, Suh H, Bershteyn A, et al. (2011) Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 10: 243-251.
    [85] Tyagi RK, Garg NK, Sahu T (2012) Vaccination strategies against malaria: novel carrier(s) more than a tour de force. J Control Release 162: 242-254.
    [86] Adler-Moore J, Munoz M, Kim H, et al. (2011) Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine. Vaccine 29: 4460-4468.
    [87] Monslow MA, Elbashir S, Sullivan NL, et al. (2020) Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates. Vaccine 38: 5793-5802.
    [88] Erasmus JH, Archer J, Fuerte-Stone J, et al. (2020) Intramuscular delivery of replicon RNA encoding ZIKV-117 human monoclonal antibody protects against Zika virus infection. Mol Ther Methods Clin Dev 18: 402-414.
    [89] Freyn AW, da Silva JR, Rosado VC, et al. (2020) A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol Ther 28: 1569-1584.
    [90] Lo MK, Spengler JR, Welch SR, et al. (2020) Evaluation of a single-dose nucleoside-modified messenger RNA vaccine encoding Hendra virus-soluble glycoprotein against lethal Nipah virus challenge in Syrian hamsters. J Infect Dis 221: S493-S498.
    [91] Yang T, Li C, Wang X, et al. (2020) Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle. Bioact Mater 5: 1053-1061.
    [92] Moyo N, Wee EG, Korber B, et al. (2020) Tetravalent immunogen assembled from conserved regions of HIV-1 and delivered as mRNA demonstrates potent preclinical T-cell immunogenicity and breadth. Vaccines (Basel) 8: 360.
    [93] Lou G, Anderluzzi G, Schmidt ST, et al. (2020) Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection. J Control Release 325: 370-379.
    [94] Mai Y, Guo J, Zhao Y, et al. (2020) Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity. Cell Immunol 354: 104143.
    [95] Eygeris Y, Patel S, Jozic A, et al. (2020) Deconvoluting lipid nanoparticle structure for messenger RNA delivery. Nano Lett 20: 4543-4549.
    [96] Van Hoecke L, Verbeke R, De Vlieger D, et al. (2020) mRNA encoding a bispecific single domain antibody construct protects against influenza A virus infection in mice. Mol Ther Nucleic Acids 20: 777-787.
    [97] Zhong Z, Mc Cafferty S, Combes F, et al. (2018) mRNA therapeutics deliver a hopeful message. Nano Today 23: 16-39.
    [98] Bogers WM, Oostermeijer H, Mooij P, et al. (2015) Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J Infect Dis 211: 947-955.
    [99] Jackson LA, Anderson EJ, Rouphael NG, et al. (2020) An mRNA vaccine against SARS-CoV-2—preliminary report. N Engl J Med . doi: 10.1056/NEJMoa2022483
    [100] Alberer M, Gnad-Vogt U, Hong HS, et al. (2017) Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390: 1511-1520.
    [101] Bahl K, Senn JJ, Yuzhakov O, et al. (2017) Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther 25: 1316-1327.
    [102] Feldman RA, Fuhr R, Smolenov I, et al. (2019) mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine 37: 3326-3334.
    [103] Ding Y, Jiang Z, Saha K, et al. (2014) Gold nanoparticles for nucleic acid delivery. Mol Ther 22: 1075-1083.
    [104] Liu J, Miao L, Sui J, et al. (2020) Nanoparticle cancer vaccines: Design considerations and recent advances. Asian J Pharm Sci . doi: 10.1016/j.ajps.2019.10.006
    [105] Yeom JH, Ryou SM, Won M, et al. (2013) Inhibition of xenograft tumor growth by gold nanoparticle-DNA oligonucleotide conjugates-assisted delivery of BAX mRNA. PLoS One 8: e75369.
    [106] Azmi F, Ahmad Fuaad AAH, Skwarczynski M, et al. (2014) Recent progress in adjuvant discovery for peptide-based subunit vaccines. Hum Vaccin Immunother 10: 778-796.
    [107] Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: Putting innate immunity to work. Immunity 33: 492-503.
    [108] Reed SG, Orr MT, Fox CB (2013) Key roles of adjuvants in modern vaccines. Nat Med 19: 1597-1608.
    [109] Oleszycka E, Lavelle EC (2014) Immunomodulatory properties of the vaccine adjuvant alum. Curr Opin Immunol 28: 1-5.
    [110] Alving CR (2009) Vaccine adjuvants. Vaccines for Biodefense and Emerging and Neglected Diseases London: Elsevier, 115-129.
    [111] Hussein WM, Liu TY, Skwarczynski M, et al. (2014) Toll-like receptor agonists: a patent review (2011–2013). Expert Opin Ther Pat 24: 453-470.
    [112] Montomoli E, Piccirella S, Khadang B, et al. (2011) Current adjuvants and new perspectives in vaccine formulation. Expert Rev Vaccines 10: 1053-1061.
    [113] Mamo T, Poland GA (2012) Nanovaccinology: The next generation of vaccines meets 21st century materials science and engineering. Vaccine 30: 6609-6611.
    [114] Banchereau J, Briere F, Caux C, et al. (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811.
    [115] Oyewumi MO, Kumar A, Cui ZR (2010) Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 9: 1095-1107.
    [116] Marasini N, Skwarczynski M, Toth I (2014) Oral delivery of nanoparticle-based vaccines. Expert Rev Vaccines 13: 1361-1376.
    [117] Kawai T, Akira S (2011) Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34: 637-650.
    [118] Vasilichin VA, Tsymbal SA, Fakhardo AF, et al. (2020) Effects of metal oxide nanoparticles on Toll-like receptor mRNAs in human monocytes. Nanomaterials (Basel) 10: 127.
    [119] Roy R, Kumar D, Sharma A, et al. (2014) ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice. Toxicol Lett 230: 421-433.
    [120] De Temmerman M-L, Rejman J, Demeester J, et al. (2011) Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov Today 16: 569-582.
    [121] Hafner AM, Corthésy B, Merkle HP (2013) Particulate formulations for the delivery of poly(I: C) as vaccine adjuvant. Adv Drug Deliv Rev 65: 1386-1399.
  • This article has been cited by:

    1. James C. L. Chow, Computational physics and imaging in medicine, 2025, 22, 1551-0018, 106, 10.3934/mbe.2025005
  • Reader Comments
  • © 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(13832) PDF downloads(1006) Cited by(19)

Figures and Tables

Figures(3)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog